Anas Ahmed
Pulmonary Disease · Omaha, NENPI 1629410824
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,711 of the $2,795 with a category attached, or 61.2%. Covidien LP accounts for 88.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,513 and has fallen 98.2% since, to $46 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NE, where the typical reported total is $2,614.
Across 22 payments — averaging $127.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$2K
- GSK$70
- AstraZeneca$68
- Boehringer Ingelheim$49
- Sanofi$48
- Philips North America LLC$27
- plus $61 from 4 others
What the payments were for
- Travel & lodging$1,71161%
- Food & beverage$1,08439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 6 | $2,472 |
| GSK | 4 | $70 |
| AstraZeneca | 3 | $68 |
| Boehringer Ingelheim | 2 | $49 |
| Sanofi | 2 | $48 |
| Philips North America LLC | 1 | $27 |
| United Therapeutics Corporation | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Bayer | 1 | $13 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$2,426
How this compares
$2,795 in reported general payments places this provider in the 50th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 362 | $258,743 |
| OfevNintedanib Esylate | 17 | $225,233 |
| TezspireTezepelumab-Ekko | 17 | $76,213 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $65,629 |
| NucalaMepolizumab | 12 | $41,610 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $39,872 |
| Incruse ElliptaUmeclidinium Bromide | 87 | $32,766 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $26,035 |
| Spiriva RespimatTiotropium Bromide | 39 | $21,722 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 79 | $17,544 |
| Arnuity ElliptaFluticasone Furoate | 21 | $9,164 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $8,181 |
| DuleraMometasone/Formoterol | 18 | $6,727 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 188 | $5,808 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $70 | $408,191631 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $49 | $246,95656 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $68 | $145,565132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.